Clostridium News and Research

RSS

U-M researchers explore prevention measures, treatments for C. difficile infection

Clostridium difficile, a wily, familiar bacterium, causes a growing number of serious infections in U.S. hospitals and nursing homes. With a $7.5 million, five-year award from the National Institutes of Health, University of Michigan researchers plan to discover what factors in the microbe and in patients make C. difficile a formidable, costly problem.

27 Aug 2010

Enteric microbiome affects disease susceptibility, provides therapeutic target for food-borne diseases: Research

At any given time, trillions of tiny microbes some helpful, some harmful are living on and in humans, forming communities and outnumbering the body's own cells tenfold. Using a $7.3 million federal grant that establishes a new cooperative research center at Michigan State University, a group of investigators is studying the microbes that live in our intestines, analyzing the role they play in food- and water-borne illnesses that kill millions of people each year worldwide.

20 Aug 2010

Calif. considers reduction in funding for home care aides; Ill. union workers strike over health issues at uranium conversion plant

California, facing a $19.1 billion budget gap, is considering a reduction in funding that pays for home care aides for the disabled. It already cut funds last year. … Last month, the nation celebrated the 20th anniversary of the Americans With Disabilities Act … Now, though, gains made under the ADA are running into recession-battered state budgets.

10 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.

7 Aug 2010

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

6 Aug 2010

Optimer second-quarter net loss decreases to $10.4 million

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.

5 Aug 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

FDA clears Meridian Bioscience's new illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene™ C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

14 Jul 2010

Strategies to prevent HACs, reduce cost of care, improve patient experience discussed at QUEST National Meeting

As healthcare providers prepare for the implications of reform, the more than 200 hospitals participating in the QUEST: High Performing Hospitals collaborative are already achieving the goals of improving patient care and reducing costs.

13 Jul 2010

Meridian Bioscience, DiaSorin sign world-wide product development and distribution agreement

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has entered into an exclusive, world-wide product development and distribution agreement with DiaSorin S.p.A. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop several infectious disease products for use on their LIAISON systems.

8 Jul 2010

Ecolab launches Virasept to treat Clostridium difficile spores

Ecolab Inc. today announced the launch of Virasept, Ecolab's first ready-to-use (no mixing required) hard surface disinfectant approved by the U.S. Environmental Protection Agency to be effective against Clostridium difficile spores.

1 Jul 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

MRSA survivors unite across the globe to raise awareness and educate public on prevention

MRSA Survivors Network with MRSA survivors, family members and other victims of healthcare-acquired infections unite across the globe and on World MRSA Day, October 2, 2010 in a grassroots movement to raise awareness and push for more mandated reporting of infections, MRSA screening laws, funds to raise awareness and educate the public on prevention, which will save lives.

15 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

Effective antimicrobial products can reduce hospital-acquired infections

The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.

14 Jun 2010

Inquiry into the hospital acquired killer bug starts

A Second World War veteran John Boyle died of Clostridium difficile infection after being admitted to hospital for the first time at the age of 90. He was diagnosed with the infection on January 25 this year and succumbed to it two weeks later. He was one of 18 patients to die at a Scottish hospital when the outbreak of this hospital-acquired infection was reported.

8 Jun 2010

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Xenex Healthcare Services LLC, which specializes in developing disinfection technology for healthcare facilities, today announced the commercial launch of its pulsed xenon room disinfection system and the conclusion of the Xenex system's successful trial at a leading U.S. cancer center. The Xenex system, which is now available, is the fastest, safest, and most effective method for the advanced cleaning of hospital rooms in the world today, quickly destroying all major classes of microorganisms (including viruses, bacteria and bacterial spores) without contact or chemicals.

8 Jun 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Clostridium News and Research

U-M researchers explore prevention measures, treatments for C. difficile infection

Enteric microbiome affects disease susceptibility, provides therapeutic target for food-borne diseases: Research

Calif. considers reduction in funding for home care aides; Ill. union workers strike over health issues at uranium conversion plant

Progenics second-quarter total revenue decreases to $2.3 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Optimer second-quarter net loss decreases to $10.4 million

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

FDA clears Meridian Bioscience's new illumigene C. difficile molecular amplification assay

Strategies to prevent HACs, reduce cost of care, improve patient experience discussed at QUEST National Meeting

Meridian Bioscience, DiaSorin sign world-wide product development and distribution agreement

Ecolab launches Virasept to treat Clostridium difficile spores

Daily use of probiotics reduces VAP in critically ill patients: New research

MRSA survivors unite across the globe to raise awareness and educate public on prevention

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Effective antimicrobial products can reduce hospital-acquired infections

Inquiry into the hospital acquired killer bug starts

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News